Liver dysfunction in patients with hemophilia A, B, and von Willebrand's disease.
Ninety-five patients with Hemophilia A, B and von Willebrand's disease followed over a three year period were evaluated for liver disease. Half of the patients were treated episodically and half received additional prophylactic treatment. Fifty-five per cent have significant transaminitis (elevated SGOT-SGPT), 42 per cent have biochemical evidence of chronic active liver disease and two per cent have subacute and active cirrhosis. There is an annual attack rate of Hepatitis B disease of 3.5 per cent and Hepatitis B antibody titres are present in 84 per cent. This asymptomatic liver disease requires close monitoring for clinical significance.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002353:Carrier State; D002648:Child; D006467:Hemophilia A / Q000150:complications* / Q000276:immunology / Q000628:therapy; D002836:Hemophilia B / Q000150:complications* / Q000276:immunology / Q000628:therapy; D006509:Hepatitis B / Q000209:etiology / Q000276:immunology; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology; D008107:Liver Diseases / Q000209:etiology*; D008297:Male; D012712:Serum Globulins / Q000096:biosynthesis; D065227:Transfusion Reaction; D014842:von Willebrand Diseases / Q000150:complications* / Q000276:immunology / Q000628:therapy
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D012712:Serum Globulins; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase